Metastatic Triple-Negative Breast Cancer (mTNBC) Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)

Metastatic Triple-Negative Breast Cancer (mTNBC) Market is segmented By Therapy (Chemotherapy, Immunotherapy, Targeted Therapy, Novel Drug Candidates), By Route of Administration (Oral, Parenteral, Intravitreal, Subretinal, Topical), By Distribution Channel (Hospitals, Specialty Clinics, Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD billion) for the above-mentioned segments.

Metastatic Triple-Negative Breast Cancer (mTNBC) Market is segmented By Therapy (Chemotherapy, Immunotherapy, Targeted Therapy, Novel Drug Candidates)....

Metastatic Triple-Negative Breast Cancer (mTNBC) Market Size

Market Size in USD

CAGR5%

Study Period	2024 - 2031
Base Year of Estimation	2023
CAGR	5%
Market Concentration	Medium
Major Players	G1 Therapeutics, PharmAbcine/Merck, Roche/Genentech, Bristol Myers Squibb, AstraZeneca

*Disclaimer: Major players are listed in no particular order.

*Source: Coherent Market Insights

Want to purchase customized report?
please let us know !

Metastatic Triple-Negative Breast Cancer (mTNBC) Market Analysis

The metastatic triple-negative breast cancer (mTNBC) market is estimated to be valued at USD 1.57 Bn in 2024 and is expected to reach USD 2.2 Bn by 2031, growing at a compound annual growth rate (CAGR) of 5% from 2024 to 2031. The increasing incidence of breast cancer worldwide and limited treatment options for mTNBC are major factors driving the growth of this market.

Metastatic Triple-Negative Breast Cancer (mTNBC) Market Report Snapshots

Buy Now